Life sciences firm aiming for global sales
Deliverics has launched its second product for the global life sciences research market.
It teamed up with fellow Edinburgh business R Biomedical to develop Safectin Stem.
The product is used in a process called transfection which involves transferring nucleic acids into cells.
Deliverics believes the Safectin Stem delivers a 90 per cent efficiency and is now working to get samples into laboratories around the world.
Dr Steve Howell, CEO of Deliverics, said: "Talking to our customers we noted the need for a reagent that was optimised specifically for stem cells.
"The transfection of nucleic acids into primary cells is a difficult process and market leading reagents were not providing effective solutions across many cell
"Our unique patented product offers a highly efficient and non toxic solution that has been designed with a one step protocol to take the pain out of transfection."
Dr Joe Mee, managing director of R Biomedical, said: "As a company that focuses on regenerative medicine research, R biomedical believes products that enhance the ability to introduce nucleic acids into stem cells at a high efficiency and with low toxicity are extremely important.
"Moreover, the launch of this product demonstrates how our two Scottish companies can bring their specialist skills together to expedite the development of high quality and important products.
The Technology Strategy Board and Scottish Enterprise's Smart:Scotland programme supported the development of Safectin Stem.
Generic transfection agent Safectin was launched in November last year.